Journal Article Review Research Support, Non-U.S. Gov't Epublish 5 citations
PubMed: 39310093 DOI: 10.7150/thno.98290
Empowering brain tumor management: chimeric antigen receptor macrophage therapy.
Theranostics 14(14):5725-5742
Authors: Fan Feng, Jianyu Shen, Qichao Qi, Yulin Zhang, Shilei Ni
Affiliations
- Department of Neurosurgery, Qilu Hospital and Institute of Brain and Brain-Inspired Science, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.
Abstract
Brain tumors pose formidable challenges in oncology due to the intricate biology and the scarcity of effective treatment modalities. The emergence of immunotherapy has opened new avenues for innovative therapeutic strategies. Chimeric antigen receptor, originally investigated in T cell-based therapy, has now expanded to encompass macrophages, presenting a compelling avenue for augmenting anti-tumor immune surveillance. This emerging frontier holds promise for advancing the repertoire of therapeutic options against brain tumors, offering potential breakthroughs in combating the formidable malignancies of the central nervous system. Tumor-associated macrophages constitute a substantial portion, ranging from 30% to 50%, of the tumor tissue and exhibit tumor-promoting phenotypes within the immune-compromised microenvironment. Constructing CAR-macrophages can effectively repolarize M2-type macrophages towards an M1-type phenotype, thereby eliciting potent anti-tumor effects. CAR-macrophages can recruit T cells to the brain tumor site, thereby orchestrating a remodeling of the immune niche to effectively inhibit tumor growth. In this review, we explore the potential limitations as well as strategies for optimizing CAR-M therapy, offering insights into the future direction of this innovative therapeutic approach.
MeSH
Brain Neoplasms, Cells, Nanomedicine, Macrophages, Brain, Neoplasms, Phenotype, Receptors, Antigen, Receptors, Chimeric Antigen, Therapeutics
Cited by
- sLithospermic acid etched ZIF-8 nanoparticles delays osteoarthritis progression by inhibiting inflammatory signaling pathways and rescuing mitochondrial damage. Mater Today Bio, 2025
- Harnessing myeloid cells in cancer. Mol Cancer, 2025
- Zirconium-89-Oxine Cell Tracking by PET Reveals Preferential Monocyte Recruitment to Cancer and Inflammation over Macrophages. Pharmaceuticals (Basel), 2025
- Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors. Curr Issues Mol Biol, 2025
- Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy. Exp Hematol Oncol, 2025
- Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review. Front Immunol, 2025